The AAPS Journal

, 21:51 | Cite as

Dissolution Chamber for Small Drug Delivery System in the Periodontal Pocket

  • Wei Ren
  • Michael Murawsky
  • Terri La Count
  • Apipa Wanasathop
  • Xin Hao
  • Gary R. Kelm
  • Darby Kozak
  • Bin Qin
  • S. Kevin LiEmail author
Research Article


Existing dissolution chambers have relatively large volume compared to the size of the periodontal pocket. A small volume dissolution method that simulates the physiological release environment for periodontal drug delivery is needed. The objectives were to construct a small, more physiologically relevant, dissolution chamber and investigate the properties of the new dissolution chamber for the assessment of sustained drug release systems in periodontal delivery. Flow-through dissolution chambers were constructed using three-dimensional (3D) printing. Drug release experiments were performed using the dissolution chamber and a commercially available long-acting periodontal insert product, PerioChip®. Similar experiments were performed under more traditional larger volume bulk solution conditions for comparison. Computer simulations and experimental results showed that drug clearance from the dissolution chamber was fast compared to drug release from the periodontal product. Drug clearance from the flow-through dissolution chamber and drug release from the sustained release product in the chamber were related to the dissolution medium flow rate and chamber volume. Drug release in the flow-through chamber was slower than that observed in bulk solution, but approached it when the medium flow rate increased. The presence of trypsin in the dissolution medium enhanced drug release from the product. A flow-through dissolution system was constructed that could evaluate drug release from a sustained release product in a small dimension environment by modifying the flow rate and composition of the dissolution medium.


chlorhexidine dissolution study drug release in vitro release testing (IVRT) periodontal pocket 



Funding for this project was made possible, in part, by the U.S. Food and Drug Administration (FDA) through a cooperative agreement (Research Award U01 FD005446). The views expressed in this paper do not reflect the official policies of the Department of Health and Human Services; nor does any mention of trade names, commercial practices, or organization imply endorsement by the United States Government. The authors thank Yuchan Yuan, Dr. Phillip Simmers, and Dr. Jason Heikenfeld for their assistance in 3D printing, Sarah R. Li for her help in the preliminary study of Comsol modeling, and Dr. Yuan Zou and Dr. Ross Walenga for helpful discussion.


This article reflects the views of the authors and should not be construed to represent the U.S. Food and Drug Administration’s views or policies.


  1. 1.
    Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res. 1998;15:11–22.CrossRefGoogle Scholar
  2. 2.
    Hermans A, Abend AM, Kesisoglou F, Flanagan T, Cohen MJ, Diaz DA, et al. Approaches for establishing clinically relevant dissolution specifications for immediate release solid oral dosage forms. AAPS J. 2017;19:1537–49.CrossRefGoogle Scholar
  3. 3.
    Seidlitz A, Weitschies W. In-vitro dissolution methods for controlled release parenterals and their applicability to drug-eluting stent testing. J Pharm Pharmacol. 2012;64:969–85.CrossRefGoogle Scholar
  4. 4.
    Dickinson PA, Lee WW, Stott PW, Townsend AI, Smart JP, Ghahramani P, et al. Clinical relevance of dissolution testing in quality by design. AAPS J. 2008;10:380–90.CrossRefGoogle Scholar
  5. 5.
    Ghosh P, Milewski M, Paudel K. In vitro/in vivo correlations in transdermal product development. Ther Deliv. 2015;6:1117–24.CrossRefGoogle Scholar
  6. 6.
    Friedman M, Golomb G. New sustained release dosage form of chlorhexidine for dental use. I. Development and kinetics of release. J Periodontal Res. 1982;17:323–8.CrossRefGoogle Scholar
  7. 7.
    Golomb G, Friedman M, Soskolne A, Stabholz A, Sela MN. Sustained release device containing metronidazole for periodontal use. J Dent Res. 1984;63:1149–53.CrossRefGoogle Scholar
  8. 8.
    Elkayam R, Friedman M, Stabholz A, Soskolne AW, Sela MN, Golub L. Sustained release device containing minocycline for local treatment of periodontal disease. J Control Release. 1988;7:231–6.CrossRefGoogle Scholar
  9. 9.
    Steinberg D, Friedman M, Soskolne A, Sela MN. A new degradable controlled release device for treatment of periodontal disease: in vitro release study. J Periodontol. 1990;61:393–8.CrossRefGoogle Scholar
  10. 10.
    Kassem AA, Ismail FA, Naggar VF, Aboulmagd E. Comparative study to investigate the effect of meloxicam or minocycline HCl in situ gel system on local treatment of periodontal pockets. AAPS PharmSciTech. 2014;15:1021–8.CrossRefGoogle Scholar
  11. 11.
    Zupancic S, Potrc T, Baumgartner S, Kocbek P, Kristl J. Formulation and evaluation of chitosan/polyethylene oxide nanofibers loaded with metronidazole for local infections. Eur J Pharm Sci. 2016;95:152–60.CrossRefGoogle Scholar
  12. 12.
    Khan G, Yadav SK, Patel RR, Nath G, Bansal M, Mishra B. Development and evaluation of biodegradable chitosan films of metronidazole and levofloxacin for the management of periodontitis. AAPS PharmSciTech. 2016;17:1312–25.CrossRefGoogle Scholar
  13. 13.
    Yadav NK, Nanda S, Sharma G, Katare OP. Systematically optimized ketoprofen-loaded novel proniosomal formulation for periodontitis: in vitro characterization and in vivo pharmacodynamic evaluation. AAPS PharmSciTech. 2017;18:1863–80.CrossRefGoogle Scholar
  14. 14.
    USP711. Dissolution. The United States Pharmacopeial Convention Pharmacopeial Forum. 2009.Google Scholar
  15. 15.
    USP724. Drug release. The United States Pharmacopeial Convention Pharmacopeial Forum. 2013.Google Scholar
  16. 16.
    Dexcel-Pharma-Technologies. PerioChip product insert. 2010.Google Scholar
  17. 17.
    Killoy WJ. The use of locally delivered chlorhexidine in the treatment of periodontitis. Clinical results. J Clin Periodontol. 1998;25:953–8.CrossRefGoogle Scholar
  18. 18.
    Murawsky M, Kelm GR, Kozak D, Qin B, Zou Y, Li SK. Influencing factors on gelatin matrix for chlorhexidine delivery. Drug Dev Ind Pharm. 2019;45:314–22.CrossRefGoogle Scholar
  19. 19.
    Nassrawin NA. Changes in gingival crevicular fluid volume and flow rate during orthodontic treatment. J Dent Oral Implants. 2016;1:20–9.CrossRefGoogle Scholar
  20. 20.
    Khurshid Z, Mali M, Naseem M, Najeeb S, Zafar MS. Human gingival crevicular fluids (GCF) proteomics: an overview. Dent J (Basel). 2017;5.CrossRefGoogle Scholar
  21. 21.
    Misra DN. Interaction of chlorhexidine digluconate with and adsorption of chlorhexidine on hydroxyapatite. J Biomed Mater Res. 1994;28:1375–81.CrossRefGoogle Scholar
  22. 22.
    Zeng P, Rao A, Wiedmann TS, Bowles W. Solubility properties of chlorhexidine salts. Drug Dev Ind Pharm. 2009;35:172–6.CrossRefGoogle Scholar
  23. 23.
    Barry PH, Diamond JM. Effects of unstirred layers on membrane phenomena. Physiol Rev. 1984;64:763–872.CrossRefGoogle Scholar
  24. 24.
    Siepmann J, Siepmann F. Mathematical modeling of drug dissolution. Int J Pharm. 2013;453:12–24.CrossRefGoogle Scholar
  25. 25.
    Barros SP, Williams R, Offenbacher S, Morelli T. Gingival crevicular fluid as a source of biomarkers for periodontitis. Periodontol 2000. 2016;70:53–64.CrossRefGoogle Scholar
  26. 26.
    Sorsa T, Tervahartiala T, Leppilahti J, Hernandez M, Gamonal J, Tuomainen AM, et al. Collagenase-2 (MMP-8) as a point-of-care biomarker in periodontitis and cardiovascular diseases. Therapeutic response to non-antimicrobial properties of tetracyclines. Pharmacol Res. 2011;63:108–13.CrossRefGoogle Scholar
  27. 27.
    Jin L, Yu C, Corbet EF. Granulocyte elastase activity in static and flow gingival crevicular fluid. J Periodontal Res. 2003;38:303–10.CrossRefGoogle Scholar
  28. 28.
    Araujo J. Evaluation of the ex vivo release profile of a long-acting biodegradable periodontal dosage form in a canine periodontal disease model. FDA Contract: HHSF223201510771P.Google Scholar
  29. 29.
    Soskolne WA, Chajek T, Flashner M, Landau I, Stabholtz A, Kolatch B, et al. An in vivo study of the chlorhexidine release profile of the PerioChip in the gingival crevicular fluid, plasma and urine. J Clin Periodontol. 1998;25:1017–21.CrossRefGoogle Scholar
  30. 30.
    Goodson JM. Pharmacokinetic principles controlling efficacy of oral therapy. J Dent Res. 1989;68:1625–32.Google Scholar
  31. 31.
    Bickel M, Munoz JL, Giovannini P. Acid-base properties of human gingival crevicular fluid. J Dent Res. 1985;64:1218–20.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2019

Authors and Affiliations

  • Wei Ren
    • 1
  • Michael Murawsky
    • 1
  • Terri La Count
    • 1
  • Apipa Wanasathop
    • 1
  • Xin Hao
    • 1
  • Gary R. Kelm
    • 1
  • Darby Kozak
    • 2
  • Bin Qin
    • 2
  • S. Kevin Li
    • 1
    Email author
  1. 1.Division of Pharmaceutical Sciences, James L Winkle College of PharmacyUniversity of CincinnatiCincinnatiUSA
  2. 2.Office of Research and Standards, Office of Generic DrugsU.S. Food and Drug AdministrationSilver SpringUSA

Personalised recommendations